Nanomedicines: design, delivery and detection

✍ Scribed by Braddock, Martin

• Publisher: Royal Society of Chemistry
• Year: 2016
• Tongue: English
• Leaves: 370
• Series: RSC drug discovery series 51
• Edition: Gld
• Category: Library

✦ Synopsis

Nanomedicines and nanopharmacology is a rapidly developing and evolving field with new techniques and applications under constant development. This book will provide an overview of the chemistry of nanocarrier design and the considerations that need to be made when developing a nanomedicine. Providing an understanding of the relationship of nanocarrier, drug and targetting moieties and physico-chemical properties, this title will provide an accurate and current representation of the field by addressing the promises, prospects and pitfalls of nanomedicine. Covering a wide range of areas in detail, this book will provide an excellent companion for medicinal chemists, pharmacologists and biochemists working in industry or academia.

✦ Table of Contents

Content: Cover
Contents
Preface
Chapter 1 Design Considerations for Properties of Nanocarriers on Disposition and Efficiency of Drug and Gene Delivery
Chapter 2 Targeting Cyclins and Cyclin-dependent Kinases Involved in Cell Cycle Regulation by RNAi as a Potential Cancer Therapy
Chapter 3 Nanoparticle Carriers to Overcome Biological Barriers to siRNA Delivery
Chapter 4 Magnetic Targeting as a Vehicle for the Delivery of Nanomedicines
Chapter 5 The Development of Theranostics --
Imaging Considerations and Targeted Drug Delivery Chapter 6 The Role of Imaging in Nanomedicine Development and Clinical TranslationChapter 7 Anticancer Agent-Incorporating Polymeric Micelles: from Bench to Bedside
Chapter 8 Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101
Chapter 9 Nanodelivery Strategies in Breast Cancer Chemotherapy
Chapter 10 Developing a Predictable Regulatory Path for Nanomedicines by Accurate and Objective Particle Measurement
Chapter 11 Nanomedicine: Promises and Challenges
Chapter 12 The Challenge of Regulating Nanomedicine: Key Issues Chapter 13 Doxil® --
the First FDA-approved Nano-drug: from Basics via CMC, Cell Culture and Animal Studies to Clinical UseSubject Index
References
1.1 Introduction
1.2 Types of Nanocarriers/Nanoparticles
1.3 Physicochemical Factors that Affect Nanoparticle Efficiency
1.4 Conclusions
References
2.1 Introduction
2.2 The Cell Cycle
2.3 Deregulation of the Cell Cycle in Cancer
2.4 RNA Interference
2.5 Concluding Remarks
Acknowledgments
References
3.1 Introduction
3.2 Extracellular Barriers
3.3 Cellular Barriers
3.4 siRNA Delivery Systems
References
4.1 Introduction 4.2 External Magnetic Device4.3 Labeling Mesenchymal Stem Cells with Supraparamagnetic Iron Oxide
4.4 Adhesion of m-MSCs to the Tissue Injured Site
4.5 Animal Studies
4.6 Conclusion
Acknowledgments
References
5.1 Introduction
5.2 Theranostic Carrier Materials
5.3 Theranostics and Imaging
5.4 Conclusions
References
6.1 Introduction
6.2 Imaging for In vivo Evaluation of the Spatio-temporal Distribution Characteristics of Nanomedicines
6.3 Use of Imaging to Understand and Optimize Nanomedicine Performance
6.4 Clinical Experience and Future Considerations
References 7.1 Introduction7.2 Anticancer Agents Incorporating Micelles under Clinical Evaluation
7.3 Verification of the EPR Effect using Imaging Mass Spectrometry
7.4 Discussion and Conclusion
References
8.1 Introduction
8.2 Topoisomerase 1 Inhibitors
8.3 Hypoxia Inducible Factor-1 Inhibitors
8.4 Cancer Stem Cells
8.5 Combination Therapy
8.6 CRLX101
8.7 Conclusion
References
9.1 Introduction
9.2 Nanocarriers for Drug Delivery to Solid Tumors
9.3 Doxil®-The First FDA-approved Nano-drug
9.4 Taxane-based Nanodelivery (Abraxane® and Genexol-PM®)
9.5 CrEL-free Formulations of PTX

✦ Subjects

Nanomedicine.;Nanoparticles.;HEALTH & FITNESS;Holism.;HEALTH & FITNESS;Reference.;MEDICAL;Alternative Medicine.;MEDICAL;Atlases.;MEDICAL;Essays.;MEDICAL;Family & General Practice.;MEDICAL;Holistic Medicine.;MEDICAL;Osteopathy.